1 · Understand your starting point
Medical history, weight history, current medicines, goals and relevant symptoms are reviewed.
- Health and medication review
- Weight-management history
- Goals and prior treatment experience
MOUNJARO CARE is a clinician-led weight-management pathway that combines medical assessment, metabolic review, investigations and personalized nutrition, lifestyle and exercise guidance. Tirzepatide may be considered only after individual clinical assessment; medication is not automatically provided.
Signature Monthly Program: ₹28,000/month all-inclusive. Current offers: 30-day ₹25,200 + 5% GST (10% flat discount) · 90-day ₹67,200 + 5% GST (20% flat discount, regular ₹84,000 + 5% GST).
“A better plan doesn’t begin with restriction.
It begins with understanding.”
Your starting point deserves clarity, not judgement.
MOUNJARO CARE is SlimMD’s doctor-guided 90-day weight management program built around once-weekly Mounjaro (tirzepatide) when medically appropriate. The Signature Monthly Program is valued at ₹28,000 per month — current offers: 30-day ₹25,200 + 5% GST and 90-day ₹67,200 + 5% GST (regular ₹84,000 + 5% GST) — covering consultation, BMR analysis, medical tests and diet, lifestyle and exercise guidance — with Mounjaro and nutrition support prescribed individually and billed at prevailing MRP.
“When you understand what you’re investing in,
the journey becomes easier to trust.”
Know the structure. Understand the purpose. Then decide what feels right for you.
A clear summary of the duration, clinical-care fee, individualized prescription layer and next step.
The pathway starts with clinical information—not with an injection. Treatment decisions remain individual throughout the 90-day program.
Medical history, weight history, current medicines, goals and relevant symptoms are reviewed.
BMR analysis and investigations are used where clinically relevant to build a safer, more personalized plan.
Your clinician decides whether prescription treatment should be considered and how follow-up should be structured.
Treatment should be supervised by an appropriately qualified clinician. Before enrollment, the patient should be able to confirm the treating clinician’s identity, qualifications, registration details and consultation pathway. Those organization-specific details are not fabricated in this file and should be inserted only after verification.
Mounjaro contains tirzepatide, a once-weekly medicine that acts on GIP and GLP-1 receptors. On this page it is presented as one possible component of clinician-guided weight management—not as a stand-alone shortcut.
Whether tirzepatide is appropriate depends on the approved product information, medical history, concurrent medicines, relevant risks and clinician judgment.
Initiation, escalation, continuation, temporary interruption or discontinuation should follow the approved prescribing information and the treating clinician’s instructions. This pricing page is not a dosing guide.
“The strongest transformations are rarely built on one thing.
They are built on the right things working together.”
Each component has a distinct purpose. The design below explains not only the price, but also what the client receives, why it matters and how it supports the 90-day journey.
The consultation is the medical decision-making layer of the program. It is where suitability, goals, current health status, tolerance, adherence and next-step planning are reviewed.
BMR analysis gives context to energy needs and helps convert generic weight-loss advice into a more individualized nutrition and activity plan.
Investigations are intended to support clinical safety and identify factors that may influence weight management, treatment selection or follow-up.
This is the combined prescription-and-nutrition support component. Mounjaro is a once-weekly dual GIP/GLP-1 receptor agonist, prescribed and titrated only when medically appropriate, while protein and micronutrient support help reinforce nutrition during a calorie-controlled program. Medication is billed separately at prevailing pharmacy MRP by dose.
The behavior-change layer turns the medical plan into day-to-day action. It focuses on realistic food choices, movement, sleep, routines and sustainable adherence.

The package repeats the core care structure monthly, but the purpose evolves from assessment and initiation to optimization and sustainable continuation.
“You don’t have to transform everything today.
You only have to make today’s step count.”
The first month creates the clinical and behavioral foundation.
“Your first victory is building a starting point you can understand.”
The second month is centered on response, adherence and intelligent adjustment.
The third month focuses on preserving progress and preparing a sustainable next phase.
“Consistency grows when your plan learns from real life.”

The value of a structured program is in how the components work together rather than functioning as isolated services.
Medical suitability is reviewed before prescription treatment is initiated or continued. The program should adapt to individual health status rather than forcing every client into one fixed protocol.
Protein and micronutrient support are incorporated to help maintain a nutritionally structured diet while calorie intake is being controlled.
The plan includes practical advice around eating patterns, exercise, walking, sleep, hydration and routines so that progress is not dependent on medication alone.
Each monthly cycle is designed to create a feedback loop: measure what is happening, understand what is working, and refine the plan under clinical guidance.
“Real value isn’t simply what is included.
It’s how intelligently every part works together.”
Clinical decisions, nutrition and habits become more useful when they are connected rather than isolated.

The ₹67,200 + 5% GST figure refers to the discounted 90-day all-inclusive program fee (regular ₹84,000 + 5% GST); it covers care services described on this page. It is not presented as the total cost of medicine plus care.
Consultation & follow-ups ₹1,000 + BMR analysis ₹1,500 + medical tests ₹4,500 + Inj. Mounjaro (tirzepatide, 4 weeks) with multivitamin, protein and antacid support ₹18,000 + diet, lifestyle, exercise and follow-up advice ₹3,000. Current offers: 30-day ₹25,200 + 5% GST · 90-day ₹67,200 + 5% GST (regular ₹84,000 + 5% GST).
Four weeks of Inj. Mounjaro (tirzepatide), one month of multivitamin, protein and antacid support are already included in the ₹28,000 monthly program. Any medicine or product beyond that scope is quoted according to the actual prescription/product plan.
The Signature Monthly Program is a transparent, all-inclusive ₹28,000 per month — including four weeks of Inj. Mounjaro at the ₹18,000 medical + nutrition allocation; any additional medicine beyond the program scope is billed by prescribed dose at pharmacy MRP.
Mounjaro cost varies by formulation, dose strength and the current pharmacy MRP. Your prescription-specific medicine cost should be confirmed at the time of prescribing or purchase. Four weeks of Inj. Mounjaro are included in the ₹28,000 monthly program at the ₹18,000 allocation; additional medication beyond the program scope is billed separately.

This distinction is important for a medical program: the package structure can be fixed, while clinical decisions remain personalized.
“The structure may be consistent.
Your medical journey should still remain individual.”
The package can be defined while clinical decisions continue to adapt to the person.
“The right next step is not always the fastest one.
It is the one that makes sense for you.”
Clinical suitability comes before prescription decisions.

Structured medical weight management suits some situations better than others. Here is an honest orientation — the final answer always comes from clinical assessment.
These lists are educational orientation, not eligibility rules. Whether prescription treatment is appropriate is always the treating clinician’s decision.
| Dimension | Medication-focused pathway | MOUNJARO CARE | Lifestyle-only pathway |
|---|---|---|---|
| Medical assessment | Depends on provider | Structured clinical assessment | Varies by provider |
| Prescription consideration | Yes, where clinically appropriate | Yes, where clinically appropriate | Not part of the pathway |
| Nutrition planning | May vary | Integrated | Usually central |
| BMR / metabolic review | Varies | Included in stated care structure | Varies |
| Lifestyle coaching | Varies | Included | Central |
| Medicine cost | Included | Included in ₹28,000 monthly program | None |
Consultation, BMR analysis, baseline investigations and suitability review. If prescribed, Mounjaro typically begins at the lowest dose while the nutrition plan is set up.
Early follow-up: tolerance, appetite changes and routine consistency are reviewed; the diet and movement plan is adjusted to real life.
Progress review. Dose continuation or titration is a clinician decision; protein targets, habits and barriers get refined.
Consolidation: response assessment, repeat tests only where indicated, and a maintenance or continuation plan for what comes after day 90.
This is a process timeline, not a results promise — individual response and pace vary and are reviewed clinically.
Mounjaro (tirzepatide) commonly causes gastrointestinal effects — nausea, reduced appetite, constipation or loose stools — most often during dose changes, and usually settling with time and dietary adjustments. Contact your treating clinician promptly for severe or persistent abdominal pain, repeated vomiting or signs of dehydration, symptoms suggesting gallbladder trouble, signs of an allergic reaction, or low-sugar symptoms if you also use insulin or sulfonylureas. Never adjust or stop a prescribed dose without medical guidance.
This overview supports informed discussion; it is not a substitute for the approved prescribing information or an individual medical consultation.
Tell the treating team about other medicines and planned procedures. Tirzepatide can affect gastrointestinal function, so medication and peri-procedure decisions may require individualized review.
Do not start, increase, reduce, skip, restart or discontinue prescription treatment on the basis of this webpage. Follow the treating clinician and the approved product information.
Severe, rapidly worsening or potentially emergency symptoms require prompt medical assessment. A website, routine message or program follow-up is not an emergency service.
The practical goal is a personalized pattern that can work with Indian foods, cultural preferences, vegetarian or non-vegetarian choices and the patient’s medical needs.
Protein targets should be individualized to support satiety, nutrition and lean-mass preservation within the overall plan.
Plans can use familiar foods—dal, curd, paneer, eggs, fish, chicken, legumes, vegetables and appropriate grains—rather than forcing a single “diet food” template.
Meal size, timing, hydration and food choices may need adjustment when appetite or gastrointestinal tolerance changes.
Individual outcomes vary. The purpose of the first 90 days is to establish assessment, treatment fit, tolerability, nutrition and behavior foundations, then decide what should happen next.
It creates defined review points for baseline assessment, early response, adherence, tolerance and consolidation without implying that medical treatment must stop at Day 90.
No individual result can be guaranteed from this webpage. Outcomes depend on starting health, adherence, treatment selection, tolerance, dose decisions, nutrition, activity and many other factors.
The treating team can reassess response and decide whether maintenance, continued structured care, medication continuation or another clinically appropriate plan is needed.
Weight management is surrounded by shortcuts, oversimplified advice and unrealistic expectations. SlimMD takes a more considered view—combining medical assessment, nutrition, lifestyle and individualized clinical decisions.
“Medical weight management is just about taking an injection.”
A structured weight-management program can involve clinical assessment, nutritional planning, movement, sleep and behavior guidance alongside prescription treatment when medically appropriate. Medication should not replace the broader foundations of long-term care.
“Everyone joining the program automatically needs Mounjaro.”
No. Prescription suitability should be determined individually by the treating clinician after reviewing medical history, current medicines, contraindications and other relevant factors.
“A higher dose automatically means better results.”
Prescription dosing should follow the treating clinician’s assessment, tolerability, approved prescribing information and individual response. More is not automatically better.
“The fastest weight loss is always the best result.”
Speed alone does not determine whether a weight-management strategy is appropriate or sustainable. Clinical context, nutritional adequacy, tolerance, adherence and longer-term planning all matter.
“If I’m using medication, diet quality doesn’t matter.”
Nutrition remains an important part of structured weight management. Meal quality, protein intake, micronutrients, hydration and practical eating habits may all form part of the plan.
“Protein powder itself causes weight loss.”
Protein supplements are a convenient nutritional tool when appropriate; they are not standalone weight-loss treatments. Their role is to help an individual meet nutritional targets where needed.
“You must exercise intensely every day to make progress.”
Activity plans can be individualized. Walking, resistance training, general daily movement and progressive exercise may all contribute depending on fitness, health and clinical suitability.
“BMR tells us exactly how much weight someone will lose.”
BMR provides useful context about baseline energy expenditure, but it does not independently predict an individual’s exact weight-management outcome.
“If Month 1 isn’t perfect, the program has failed.”
Structured weight management can involve learning and adjustment. Reviews can help identify barriers, tolerance issues, nutritional challenges and routines that may need refinement.
“After 90 days, weight management is finished forever.”
The end of a structured 90-day phase may instead become a point for review. Maintenance, continued support or another clinically appropriate plan may be discussed according to the individual’s response and goals.
This production file intentionally avoids fabricating citations. Before launch, product-specific claims should be checked against current authoritative sources.
Use the current India-approved Mounjaro/tirzepatide product information for indication, contraindications, warnings, adverse effects, administration, storage and missed-dose instructions.
Verify India-specific prescription classification, approved presentations and current pharmacy MRP before publishing dose- or price-specific statements.
Use peer-reviewed clinical-trial and guideline evidence for treatment efficacy, safety and obesity-management principles; do not convert population averages into individual promises.
Record the named medical reviewer, qualifications, registration, review date and update trigger when verified organization data is available.
MOUNJARO CARE is presented as a medically supervised weight-management pathway in which tirzepatide may be considered only when clinically appropriate—not as a self-prescribing or injection-only solution.
Clinical oversight is intended to keep each journey centered on appropriate assessment, individualized decision-making, nutrition and lifestyle support, tolerability review and planned follow-up rather than medication alone.
Profile verification before publication: Add Dr. Jyotii A Agarkar’s verified full name, qualifications, specialty/clinical designation, medical registration details, profile URL and review date before presenting this as a formal medical-review credential.
For transparency, these links lead to independent clinical and regulatory sources. They are educational references and do not replace individualized medical advice or local prescribing information.
Evidence boundary: These organizations publish independent guidance about obesity treatment and tirzepatide/GLP-1 therapy. Their inclusion does not imply endorsement of MOUNJARO CARE, SlimMD, SlimMD or any clinic or commercial program.
“Questions are not hesitation.
They are part of making an informed decision.”
MOUNJARO CARE is SlimMD’s doctor-guided 90-day weight-management pathway combining clinical review, BMR analysis, investigations as needed, and diet, lifestyle and exercise guidance. Tirzepatide may be considered when medically appropriate.
The Signature Monthly Program is valued at ₹28,000 per month: consultation and follow-ups ₹1,000, BMR analysis ₹1,500, medical tests ₹4,500, Inj. Mounjaro (tirzepatide, 4 weeks) with multivitamin, protein and antacid support ₹18,000, and diet, lifestyle, exercise and follow-up advice ₹3,000. Current offers: 30-day ₹25,200 + 5% GST (10% flat discount) and 90-day ₹67,200 + 5% GST (20% flat discount, regular ₹84,000 + 5% GST).
Yes. The ₹28,000 monthly program includes four weeks of Inj. Mounjaro (tirzepatide) along with multivitamin, protein and antacid support, as described on this page. Mounjaro and nutritional products are additional and should be quoted according to the individual prescription/product plan.
The complete 90-day program fee is currently ₹67,200 + 5% GST (regular ₹84,000 + 5% GST). The overall amount can be higher because prescription medicines and nutritional products are additional. The exact total cannot be stated until the individual plan is known.
Medicine cost can vary by approved presentation, dose strength and current pharmacy MRP. Current prescription-specific pricing should be confirmed at the time of prescribing or purchase.
No. Prescription treatment should be considered only when the treating clinician determines that it is medically appropriate after reviewing the individual’s history, medicines, relevant risks and overall suitability.
The decision can include weight and medical history, current medicines, relevant conditions and symptoms, prior treatment experience, investigations where needed, goals and the approved prescribing information.
Not necessarily. Investigations and their timing should be based on clinical need. The page shows a ₹4,500 monthly test allocation because that is the supplied package structure.
The supplied source does not define this commercial policy. The clinic should confirm the rule before enrollment; this webpage does not invent a refund, credit or carry-forward policy.
BMR analysis provides context for energy needs and can support nutrition and activity planning. It is one input within a broader clinical assessment, not a stand-alone predictor of outcomes.
No. The pathway also includes medical supervision, metabolic context, investigations where relevant, nutrition planning, lifestyle guidance and exercise advice.
Whether SlimMD offers a non-tirzepatide version under the same commercial package is an operational question that should be confirmed directly. Clinically, weight management can use multiple approaches and medication is not appropriate for everyone.
Do not change or duplicate treatment based on this page. Tell the treating clinician exactly what you are using, including dose, timing and any side effects, so the clinician can review safety and next steps.
The nutrition framework can be individualized for vegetarian and non-vegetarian preferences. Protein and micronutrient recommendations should reflect the person’s diet, health needs and tolerance.
Contact the treating team for persistent or troublesome symptoms. Severe, rapidly worsening or potentially emergency symptoms require prompt medical assessment. Do not self-adjust prescription treatment using website information.
Pregnancy, breastfeeding and reproductive planning require specific medical discussion before prescription treatment. The current approved product information and treating clinician’s advice should guide decisions.
No dosing change should be made from this webpage. Initiation and escalation should follow the approved prescribing information and treating clinician’s judgment.
No individual amount can be guaranteed. Results vary with starting health, adherence, treatment selection, tolerance, nutrition, activity and other factors.
No. A medical weight-management program can provide assessment, treatment options and structured support, but individual outcomes cannot be guaranteed.
The treating team can review response, tolerability, nutrition, behavior and ongoing goals, then decide whether maintenance, continued structured care, medication continuation or another appropriate pathway is needed.
The supplied source does not verify consultation mode or service geography. These operational details should be shown only after the organization confirms them.
Those commercial policies are not supplied in the source file. They should be confirmed before payment and published once verified; this page deliberately avoids fabricating terms.
Review the investment or move to the next-step assessment.
This front-end form helps organize information for a future clinical assessment. It does not transmit health data because no verified secure clinic endpoint was supplied with this HTML.
Clinical content reviewed under SlimMD medical editorial standards. Before publication, connect the verified reviewing clinician’s full name, qualifications, registration details and profile URL. Last content update: 30 August 2026.
This page is for general information and does not replace a medical consultation. Prescription treatment is considered only where clinically appropriate, and persistent, severe or worsening symptoms always require clinical review.